Drug
alisertib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Group | Aurora A kinase inhibitor |
| Mechanism of Action | Aurora A kinase inhibitor |
| Half-life | 16-23 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing, largely p53-dependent (G2/M arrest, sustained DSBs, mitotic catastrophe) (Li et al. International Journal of Radiation Oncology, Biology, Physics 2023; Moretti et al. International Journal of Radiation Oncology, Biology, Physics 2011; Chen et al. Experimental Cell Research 2026). Mitotic-checkpoint disruption is not tumor-selective, so a theoretical increase in in-field adverse events and additive myelosuppression/mucositis is plausible.
Data on this page refer exclusively to patients treated with
alisertib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Aurora A kinase inhibitor group page.